Log on / register
Feedback | Support | My details
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J
Arthritis Res Ther 2005, 7:R439-44
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

PubMed Central articles that cite the above article:

1.
How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
Sieper J, Rudwaleit M
Ann Rheum Dis 2005 Nov, 64 Suppl 4:iv61-4
 [PubMed Central] [PubMed] [Related articles]
2.
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ
Ann Rheum Dis 2005 Nov, 64 Suppl 4:iv2-14
 [PubMed Central] [PubMed] [Related articles]

This article is also cited by 1 article in BioMed Central


You can also check ISI Web of Science for additional citations (subscription required)
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2008 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.